BlackRock Inc. Buys 72796 Shares of Aerpio Pharmaceuticals Inc (OTCMKTS:ARPO)

BlackRock Inc. grew its stake in Aerpio Pharmaceuticals Inc (OTCMKTS:ARPO) by 78.8% in the 2nd quarter, according to its most recent filing with the …

Aerpio Pharmaceuticals logoBlackRock Inc. grew its stake in Aerpio Pharmaceuticals Inc (OTCMKTS:ARPO) by 78.8% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 165,222 shares of the company’s stock after purchasing an additional 72,796 shares during the quarter. BlackRock Inc. owned about 0.41% of Aerpio Pharmaceuticals worth $150,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of ARPO. US Bancorp DE bought a new position in shares of Aerpio Pharmaceuticals in the 2nd quarter worth about $46,000. Panagora Asset Management Inc. increased its stake in shares of Aerpio Pharmaceuticals by 390.2% in the 2nd quarter. Panagora Asset Management Inc. now owns 64,074 shares of the company’s stock worth $58,000 after acquiring an additional 51,003 shares in the last quarter. Finally, Acadian Asset Management LLC increased its stake in shares of Aerpio Pharmaceuticals by 23.2% in the 2nd quarter. Acadian Asset Management LLC now owns 186,550 shares of the company’s stock worth $170,000 after acquiring an additional 35,121 shares in the last quarter. Institutional investors and hedge funds own 0.37% of the company’s stock.

Several brokerages recently commented on ARPO. Zacks Investment Research raised shares of Aerpio Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.75 price objective on the stock in a research report on Wednesday, October 9th. HC Wainwright set a $1.00 price objective on shares of Aerpio Pharmaceuticals and gave the company a “hold” rating in a research report on Monday, October 21st. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Aerpio Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $3.25.

Shares of OTCMKTS ARPO opened at $0.53 on Friday. The firm’s 50-day moving average price is $0.61 and its 200-day moving average price is $0.82. Aerpio Pharmaceuticals Inc has a 52-week low of $0.45 and a 52-week high of $4.25.

Aerpio Pharmaceuticals (OTCMKTS:ARPO) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.04.

About Aerpio Pharmaceuticals

Aerpio Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes proprietary therapeutics for treating ocular diseases. The company’s lead product candidate is AKB-9778, a small molecule activator of the tie-2 pathway, which completed Phase 2a clinical trials for the treatment of diabetic macular edema.

See Also: Cost of equity and a company’s balance sheet

Institutional Ownership by Quarter for Aerpio Pharmaceuticals (OTCMKTS:ARPO)

Receive News & Ratings for Aerpio Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Aerpio Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts